A subtle initial clinical presentation of a TSH-secreting PitNET.

IF 0.9 Q4 ENDOCRINOLOGY & METABOLISM
Rosanna Buè, Lauro Gianola, Pierpaolo Trimboli
{"title":"A subtle initial clinical presentation of a TSH-secreting PitNET.","authors":"Rosanna Buè, Lauro Gianola, Pierpaolo Trimboli","doi":"10.1530/EDM-25-0082","DOIUrl":null,"url":null,"abstract":"<p><strong>Summary: </strong>Thyroid stimulating hormone (TSH)-secreting PitNETs, also called TSHomas, are rare benign pituitary tumors with an incidence of 1.0 per million population. They are generally diagnosed in the context of central hyperthyroidism and/or mass-effect central symptomatology (e.g. headache, bitemporal hemianopsia, and panhypopituitarism). Although TSHomas are more often macroadenomas than microadenomas at the time of diagnosis, diagnosing TSHomas may be challenging because laboratory findings and clinical presentation are not always obvious. The treatment of choice is the surgical resection of the adenoma.</p><p><strong>Learning points: </strong>TSHomas are mostly diagnosed as macroadenomas in the context of central hyperthyroidism and/or mass-effect central symptomatology. The classical pattern of central hyperthyroidism consists of elevated free thyroid hormones and inadequately normal or slightly increased TSH. If a TSHoma is suspected, the differential diagnosis of thyroid hormone resistance (RTH) must be excluded. Surgical resection is the first-line choice of therapy for TSHomas. In cases of non-operable lesions or postoperative residual tumors, pituitary fractionated stereotactic radiotherapy, radiosurgery, and/or medical treatment with somatostatin analogs can be considered as alternatives. The management of TSHomas must happen in an interdisciplinary way.</p>","PeriodicalId":37467,"journal":{"name":"Endocrinology, Diabetes and Metabolism Case Reports","volume":"2025 4","pages":""},"PeriodicalIF":0.9000,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12603896/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrinology, Diabetes and Metabolism Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1530/EDM-25-0082","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/1 0:00:00","PubModel":"Print","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Summary: Thyroid stimulating hormone (TSH)-secreting PitNETs, also called TSHomas, are rare benign pituitary tumors with an incidence of 1.0 per million population. They are generally diagnosed in the context of central hyperthyroidism and/or mass-effect central symptomatology (e.g. headache, bitemporal hemianopsia, and panhypopituitarism). Although TSHomas are more often macroadenomas than microadenomas at the time of diagnosis, diagnosing TSHomas may be challenging because laboratory findings and clinical presentation are not always obvious. The treatment of choice is the surgical resection of the adenoma.

Learning points: TSHomas are mostly diagnosed as macroadenomas in the context of central hyperthyroidism and/or mass-effect central symptomatology. The classical pattern of central hyperthyroidism consists of elevated free thyroid hormones and inadequately normal or slightly increased TSH. If a TSHoma is suspected, the differential diagnosis of thyroid hormone resistance (RTH) must be excluded. Surgical resection is the first-line choice of therapy for TSHomas. In cases of non-operable lesions or postoperative residual tumors, pituitary fractionated stereotactic radiotherapy, radiosurgery, and/or medical treatment with somatostatin analogs can be considered as alternatives. The management of TSHomas must happen in an interdisciplinary way.

Abstract Image

Abstract Image

Abstract Image

分泌tsh的PitNET的初步临床表现。
摘要:促甲状腺激素(TSH)分泌PitNETs,也称为TSHomas,是一种罕见的良性垂体肿瘤,发病率为百万分之1.0。他们通常被诊断为中枢性甲状腺功能亢进和/或质量效应中枢性症状(如头痛、双颞偏盲和全垂体功能减退)。尽管tshoma在诊断时多为大腺瘤而非微腺瘤,但由于实验室结果和临床表现并不总是明显,因此诊断tshoma可能具有挑战性。治疗的选择是手术切除腺瘤。学习要点:在中枢性甲状腺功能亢进和/或质量效应中枢症状的背景下,tshoma大多被诊断为大腺瘤。中枢性甲状腺机能亢进的典型特征是游离甲状腺激素升高和TSH不正常或轻度升高。如果怀疑TSHoma,必须排除甲状腺激素抵抗(RTH)的鉴别诊断。手术切除是tshoma的首选治疗方法。对于无法手术的病变或术后残留肿瘤,垂体分形立体定向放疗、放射外科手术和/或使用生长抑素类似物进行药物治疗可以考虑作为替代方案。tshoma的管理必须以跨学科的方式进行。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.50
自引率
0.00%
发文量
142
审稿时长
9 weeks
期刊介绍: Endocrinology, Diabetes & Metabolism Case Reports publishes case reports on common and rare conditions in all areas of clinical endocrinology, diabetes and metabolism. Articles should include clear learning points which readers can use to inform medical education or clinical practice. The types of cases of interest to Endocrinology, Diabetes & Metabolism Case Reports include: -Insight into disease pathogenesis or mechanism of therapy - Novel diagnostic procedure - Novel treatment - Unique/unexpected symptoms or presentations of a disease - New disease or syndrome: presentations/diagnosis/management - Unusual effects of medical treatment - Error in diagnosis/pitfalls and caveats
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书